Best Value Stocks To Buy For 2023

Raven Industries, Inc. (RAVN Quick QuoteRAVN ) announced an update on its deal with CNH Industrial N.V. (CNHI Quick QuoteCNHI ) , signed in June 2021. The transaction was green lighted by the company’s shareholders at a special meeting held yesterday.

In the last trading session, shares of Raven dipped 0.24%, closing at $57.60.

Raven is based in Sioux Falls, SD and is one of the leading companies engaged in providing precision agriculture technology. It has three divisions, namely Aerostar, Engineered Films and Applied Technology. Its revenues totaled $348.4 million in the 12 months ended Jan 31, 2021.

Inside the Headlines

The deal was approved by 99% of the nearly 71% of Raven’s stakeholders that voted at the special meeting. The completion of the transaction is expected in the fourth quarter of 2021 after receiving necessary approvals from the Defense Counterintelligence and Security Agency (DCSA) and the Committee on Foreign Investment in the United States (CFIUS).

A brief discussion on the signed agreement is provided below:

The deal inked between the parties calls for the buyout of Raven by CNH Industrial. The transaction was valued at $58 per share or $2.1 billion enterprise value and will be funded by CNH Industrial with available cash.

The transaction is expected to enhance Raven’s capabilities in the agriculture technology space and boost its shareholder value. CNH Industrial plans to take a strategic review of Aerostar and Engineered Films divisions after the transaction is over. While Aerostar is a leader in the stratospheric platform industry, Engineered Films is well-known in the performance specialty films industry. The review will help boost the capabilities of both divisions and enhance shareholder value.

By calendar year 2025, the Raven-CNH Industrial transaction is anticipated to generate revenues (run-rate) worth $400 million. Incremental earnings before interest, tax, depreciation and amortization are expected to be $150 million.

Best Value Stocks To Buy For 2023: Genomic Health, Inc.(GHDX)

Genomic Health, Inc., incorporated on August 22, 2000, is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score (GPS) for prostate cancer.

The Company’s Oncotype DX tests analyze the expression levels of various genes across various biological pathways. Its offerings also include Oncotype DX Breast Cancer Test, Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test. The Oncotype DX breast, colon and prostate cancer tests analyze various genes and are based on its Oncotype DX RT-PCR platform. The Company offers its services and products through its Oncotype IQ Genomic Intelligence Platform. Its Oncotype IQ Genomic Intelligence Platform product pipeline also includes products for tumor monitoring under its Oncotype TRACK for various cancer types. The Company offers its testing services through its clinical reference laboratory located in Redwood City.

Oncotype DX Tests

The Company’s Oncotype DX tests utilize quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. Its diagnostic approach correlates gene expression to clinical outcomes and provides an individualized analysis of each patient’s tumor. The Company’s technologies allow it to analyze tumor tissue samples in its clinical reference laboratory and provide physicians with genomic information specific to the patient’s tumor. The Company analyzes tissues that are handled, processed and stored under routine clinical pathology laboratory practices.

The Company competes with Roche Holding, Ltd, Siemens AG, Guardant Health, Johnson & Johnson, NanoString Technologies Inc., BioTheranostics, Sividon Diagnostics, Myriad Genetics Inc., NeoGenomics Laboratories, GenomeDx Biosciences Inc., Agendia Inc., Hologic Inc., Novartis AG, Qiagen N.V., Foundation Medicine, Grail, MDxHealth, Natera Inc., Trovagene Inc., Laboratory Corporation of America Holdings and Quest Diagnostics Incorporated.

Advisors’ Opinion:

  • [By Shane Hupp]

    Genomic Health (NASDAQ:GHDX) was downgraded by investment analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a note issued to investors on Tuesday.

  • [By Maxx Chatsko]

    Despite all the progress, Invitae is still the least mature business among its publicly traded peers, including Genomic Health (NASDAQ:GHDX) and Myriad Genetics (NASDAQ:MYGN). Here’s how it compares to its closest competitors:

Best Value Stocks To Buy For 2023: Ryder System Inc.(R)

Ryder System, Inc. provides transportation and supply chain management solutions. It operates in three segments: Fleet Management Solutions (FMS), Supply Chain Solutions (SCS), and Dedicated Contract Carriage (DCC). The FMS segment offers leasing, contract maintenance, contract-related maintenance, and commercial rental of trucks, tractors, and trailers primarily in the United States, Canada, and the United Kingdom. It also offers fleet support services, such as fuel, insurance, safety, administration, environmental management, and information technology services. In addition, this segment sells its used vehicles through 55 company owned retail sales centers, as well as through its Web site, Its customers include small businesses and enterprises operating in transportation, grocery, lumber and wood products, food service, and home furnishings industries. The SCS segment provides supply chain consulting solutions in North America and Asia. It offers di stribution management, transportation management, and professional services, as well as various support services, such as information technology and engineering solutions. This segment primarily serves automotive, electronics, high-tech, telecommunications, industrial, consumer goods, consumer packaged goods, paper and paper products, office equipment, food and beverage, and general retail industries. The DCC segment offers vehicles and drivers as part of a transportation solution in the United States. It combines the equipment, maintenance, and administrative services of a service lease with drivers and additional services, such as routing and scheduling, fleet sizing, safety, regulatory compliance, risk management, technology and communication systems support, and other technical support. This segment serves energy and utility, metals and mining, retail, construction, healthcare products, and food and beverage industries. The company was founded in 1933 and is based in Mia mi, Florida.

Advisors’ Opinion:

  • [By Max Byerly]

    Ryder System (NYSE:R) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Thursday.

  • [By Logan Wallace]

    Red Eagle Mining Corp (TSE:R) Director Ian Slater acquired 1,000,000 shares of the firm’s stock in a transaction that occurred on Monday, August 27th. The stock was purchased at an average cost of C$0.12 per share, with a total value of C$120,000.00.

  • [By Stephan Byrd]

    American Century Companies Inc. grew its position in Ryder System, Inc. (NYSE:R) by 63.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 449,060 shares of the transportation company’s stock after acquiring an additional 175,020 shares during the quarter. American Century Companies Inc.’s holdings in Ryder System were worth $32,269,000 as of its most recent SEC filing.

Best Value Stocks To Buy For 2023: Reliv’ International Inc.(RELV)

Reliv? International, Inc. develops, manufactures, and markets nutritional supplements. Its basic nutrition supplements include Reliv Classic and Reliv NOW, a blend of vitamins, minerals, proteins, and herbs; NOW for Kids, which provides a balanced nutritional supplement for a child?s diet; and Reliv Delight, a powdered nutritional supplement marketed as a milk replacement. The company?s specific wellness supplements comprise ReversAge, a nutritional supplement to slow down the effects of the aging process; SoySentials for use by women; CardioSentials that promotes heart health; Arthaffect, which supports healthy joint function; FibRestore that contains fiber, vitamins, minerals, and herbs; GlucAffect, which assists in healthy blood sugar management and support weight loss; and 24K, a ready-to-drink nutritional supplement that enhances the body?s natural vitality. Its weight management supplements consist of Slimplicity meal replacement and accelerator capsules; Reliv Ultrim-Plus, a meal replacement product; and Cellebrate, a weight loss aid. The company?s sports nutrition supplements include Innergize!, a sports supplement containing vitamins and minerals for performance enhancement; and ProVantage to enhance muscle recovery, muscle mass, and function, as well as to reduce fatigue and burn excess body fat for extra energy. It also offers Relivables product line, which comprises skin care products, marketed as the ?r? skin care collection, as well as food products, such as Relivables All-Natural Sweetener, Relivables Fortified Soy Milk, Relivables Soy Nuts, and Relivables Healthy Snack Bars. Reliv? International markets and sells its products through a network of independent distributors in the United States, Australia, Austria, Brunei, Canada, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, Singapore, and the United Kingdom. The company was founded in 1984 and is headquartered in Chesterf ield, Missouri.

Advisors’ Opinion:

  • [By Ethan Ryder]

    Headlines about Reliv International (NASDAQ:RELV) have trended somewhat positive recently, according to Accern. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Reliv International earned a news sentiment score of 0.06 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.5816094320485 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Best Value Stocks To Buy For 2023: Occidental Petroleum Corporation(OXY)

Occidental Petroleum Corporation engages in the acquisition, exploration, and development of oil and gas properties in the United States and internationally. The company operates in three segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops, and produces oil and condensate, natural gas liquids (NGLs), and natural gas. The Chemical segment manufactures and markets basic chemicals, including chlorine, caustic soda, chlorinated organics, potassium chemicals, ethylene dichloride, chlorinated isocyanurates, sodium silicates, and calcium chloride; vinyls comprising vinyl chloride monomer and polyvinyl chloride; and other chemicals, such as resorcinol. The Midstream and Marketing segment gathers, processes, transports, stores, purchases, and markets oil, condensate, NGLs, natural gas, carbon dioxide, and power. This segment also trades around its assets consisting of transportation and storage capacity, as well as oil, NGLs, gas, and other commodities. Occidental Petroleum Corporation was founded in 1920 and is headquartered in Houston, Texas.

Advisors’ Opinion:

  • [By Evan Niu, CFA]

    Shares of Celestica (NYSE:CLS) have plunged today, down by 16% as of 10:45 a.m. EST, after the company reported fourth-quarter earnings results. The electronics manufacturing specialist missed earnings estimates and forecast first-quarter earnings below expectations as well.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Celestica (CLS)

    For more information about research offerings from Zacks Investment Research, visit

Best Value Stocks To Buy For 2023: Cassava Sciences, Inc.(SAVA)

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Advisors’ Opinion:

  • [By Louis Navellier and the InvestorPlace Research Staff]

    Since biotechnology company Cassava Sciences (NASDAQ:SAVA) is working hard to fight Alzheimer’s disease, it might be surprising to know that the company has some harsh critics. There’s a lot of drama going on with Cassava, and SAVA stock traders need to be aware of the latest developments.

  • [By Larry Ramer]

    Allegations of fraud against Cassava Sciences (NASDAQ:SAVA) are unlikely to stop its Alzheimer’s drug candidate from quickly advancing to a Phase 3 clinical trial. As a result, I remain very bullish on SAVA stock.

Leave a Reply

Your email address will not be published.